Praxis Precision Medicines (PRAX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec12

UBS Asset Management Reduced Stake in Praxis Precision Medicines in Q2

10:47

Dec11

Praxis Precision Plans to Submit New Drug Application for Relutrigine in Early 2026

13:00

HighVista Strategies LLC Increased its Stake in Praxis Precision Medicines

12:29

Dec9

Praxis Precision Medicines Inc. Obtains FDA Approval for elsunersen Monotherapy Study

21:01

Dec8

Truist Financial Raises Praxis Precision Medicines Price Target to $500

15:56

Needham Maintains 'Buy' Rating on Praxis Precision Medicine and Raises Target Price

15:36

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -73.93 M, EPS -3.3641

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -71.13 M, EPS -3.3121

May2

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -69.3 M, EPS -3.291

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change